[Monotherapy trial with selegiline in de novo parkinsonian patients] Members of the French research group for testing selegiline in early Parkinson disease].
Identifieur interne : 001675 ( PubMed/Curation ); précédent : 001674; suivant : 001676[Monotherapy trial with selegiline in de novo parkinsonian patients] Members of the French research group for testing selegiline in early Parkinson disease].
Auteurs :Source :
- Therapie [ 0040-5957 ]
Descripteurs français
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Selegiline.
- geographic : France.
- drug therapy : Parkinson Disease.
- Aged, Double-Blind Method, Drug Evaluation, Female, Humans, Male, Middle Aged.
Abstract
The French selegiline (S) multicenter trial was conducted in 1990 to test the possibility to improve symptomatology of de novo parkinsonian patients (PP) during the first three months of treatment by monotherapy S 10 mg/day. A randomized double blind placebo, parallel controlled trial was carried out on 93 patients in 13 neurologic centers. S appears superior to placebo. Global scores and motor subscores of UPDRS are improved (p < 0.001, p < 0.01) from the first to the third month. Side effects are minor (nausea, dysgueusia, vertigo, lipothymia) and hardly different in both groups. S thus appears as inducing a rapid and moderate symptomatic effect in de novo PP, during a 3 months long period of treatment.
PubMed: 8140562
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001716
Links to Exploration step
pubmed:8140562Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Monotherapy trial with selegiline in de novo parkinsonian patients] Members of the French research group for testing selegiline in early Parkinson disease].</title></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>1993 May-Jun</MedlineDate></PubDate></date><idno type="RBID">pubmed:8140562</idno><idno type="pmid">8140562</idno><idno type="wicri:Area/PubMed/Corpus">001716</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001716</idno><idno type="wicri:Area/PubMed/Curation">001675</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001675</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Monotherapy trial with selegiline in de novo parkinsonian patients] Members of the French research group for testing selegiline in early Parkinson disease].</title></analytic><series><title level="j">Therapie</title><idno type="ISSN">0040-5957</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Drug Evaluation</term><term>Female</term><term>France</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Selegiline (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Selegiline</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Drug Evaluation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The French selegiline (S) multicenter trial was conducted in 1990 to test the possibility to improve symptomatology of de novo parkinsonian patients (PP) during the first three months of treatment by monotherapy S 10 mg/day. A randomized double blind placebo, parallel controlled trial was carried out on 93 patients in 13 neurologic centers. S appears superior to placebo. Global scores and motor subscores of UPDRS are improved (p < 0.001, p < 0.01) from the first to the third month. Side effects are minor (nausea, dysgueusia, vertigo, lipothymia) and hardly different in both groups. S thus appears as inducing a rapid and moderate symptomatic effect in de novo PP, during a 3 months long period of treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8140562</PMID><DateCreated><Year>1994</Year><Month>04</Month><Day>26</Day></DateCreated><DateCompleted><Year>1994</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0040-5957</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>3</Issue><PubDate><MedlineDate>1993 May-Jun</MedlineDate></PubDate></JournalIssue><Title>Therapie</Title><ISOAbbreviation>Therapie</ISOAbbreviation></Journal><ArticleTitle>[Monotherapy trial with selegiline in de novo parkinsonian patients] Members of the French research group for testing selegiline in early Parkinson disease].</ArticleTitle><Pagination><MedlinePgn>225-31</MedlinePgn></Pagination><Abstract><AbstractText>The French selegiline (S) multicenter trial was conducted in 1990 to test the possibility to improve symptomatology of de novo parkinsonian patients (PP) during the first three months of treatment by monotherapy S 10 mg/day. A randomized double blind placebo, parallel controlled trial was carried out on 93 patients in 13 neurologic centers. S appears superior to placebo. Global scores and motor subscores of UPDRS are improved (p < 0.001, p < 0.01) from the first to the third month. Side effects are minor (nausea, dysgueusia, vertigo, lipothymia) and hardly different in both groups. S thus appears as inducing a rapid and moderate symptomatic effect in de novo PP, during a 3 months long period of treatment.</AbstractText></Abstract><Language>fre</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><VernacularTitle>Essai de la sélégiline en monothérapie chez le parkinsonien de novo. Membres du groupe de l'essai français de la sélégiline chez le parkinsonien de novo.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Therapie</MedlineTA><NlmUniqueID>0420544</NlmUniqueID><ISSNLinking>0040-5957</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2K1V7GP655</RegistryNumber><NameOfSubstance UI="D012642">Selegiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004341" MajorTopicYN="N">Drug Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012642" MajorTopicYN="N">Selegiline</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8140562</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001675 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001675 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:8140562
|texte= [Monotherapy trial with selegiline in de novo parkinsonian patients] Members of the French research group for testing selegiline in early Parkinson disease].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:8140562" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |